AstraZeneca has reported new phase III clinical trial data showing the heart health benefits of extended treatment with Brilinta.
A new sub-analysis of data from the PEGASUS-TIMI 54 trial showed that Brilinta was associated with a 29 percent reduction in the risk of cardiovascular death versus placebo in patients taking low-dose aspirin but still at high risk of an atherothrombotic event.
“AstraZeneca has reported clinical data showing how extended use of Brilinta can reduce the risk of cardiovascular death in patients with a history of heart attack.“
For this study, patients received Brilinta within two years of having a heart attack or within one year of stopping antiplatelet treatment with an adenosine diphosphate inhibitor. These results show a potential protective cardiovascular benefit associated with longer-term treatment.
Elisabeth Bjork, vice-president and head of cardiovascular and metabolic diseases for AstraZeneca's global medicines development unit, said: "The results reinforce the importance of our continued investment in the science, helping to understand better the unique cardiovascular and mortality benefits that our medicines, such as Brilinta, can provide for the millions of patients living with cardiovascular disease."
Other findings from PEGASUS-TIMI 54 showed that Brilinta was associated with a risk reduction of 20 percent across all causes of death, as well as a 20 percent drop in rates of cardiovascular death, myocardial infarction or stroke.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical